First In-human Study Update: Study Open for Enrolment

Dec 15, 2020
Posted in: News, Investor updates

Home » First In-human Study Update: Study Open for Enrolment

First In-human Study Update: Study Open for Enrolment

Dec 15, 2020
Posted in: News, Investor updates

Imagion Biosystems is pleased to announce that Monash Health has been established as the first clinical site and is ready to commence enrolment of patients for the MagSense^® HER2 breast cancer Phase I first-in-human study.

Read the announcement.

Positive Results from IBI10103 Phase I Study with MagSense® HER2 Imaging Agent

December 7, 2023

Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent Imagion Biosystems Limited

[VIDEO] EGM Recording – 13 November 2023

November 14, 2023

https://youtu.be/hThLkmpJPW0 EGM 13 November 2023 Video transcript: Welcome and thanks for joining us. Both those joining virtually and those in person. As the time is

Quarterly Activity Report – Quarter ending 30 September 2023

October 31, 2023

Highlights: Announced preliminary performance of MagSense® HER2 Imaging Agent in phase 1 study after study closure (post quarter end) Entered a strategic partnership with Prestige

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

First In-human Study Update: Study Open for Enrolment

First In-human Study Update: Study Open for Enrolment

Related Articles

Positive Results from IBI10103 Phase I Study with MagSense® HER2 Imaging Agent

[VIDEO] EGM Recording – 13 November 2023

Quarterly Activity Report – Quarter ending 30 September 2023

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list